摘要
目的:探讨丁咯地尔在预防蛛网膜下腔出血后脑血管痉挛中的效果。方法:选取某院于2014年7月~2016年7月间收治的蛛网膜下腔出血(SAH)患者76例,随机将病患分成观察组(38例)、对照组(38例),对照组术后给予常规治疗,预防脑血管痉挛的发生,观察组在对照组基础上加用丁咯地尔对脑血管痉挛进行预防,比较两组的脑血管痉挛发生率、不良反应率与血清S-100B、EPO、MMP-9指标。结果:(1)脑血管痉挛发生率:观察组为5.26%,对照组为18.42%,对比具有差异性(P<0.05);(2)观察组治疗后的血清EPO、MMP-9、S-100B指标改善效果均优于对照组,对比有差异(P<0.05);(3)不良反应率:观察组为2.63%,对照组为5.26%,对比无统计学意义(P>0.05)。结论:蛛网膜下腔出血患者利用丁咯地尔预防脑血管痉挛,有利于取得良好的预防效果,能降低脑血管痉挛发生率,值得临床推广。
Objective：To investigate the effect of buflomedil in preventing cerebral vasospasm after subarachnoid hemorrhage.Methods：76patients with subarachnoid hemorrhage（SAH）from July 2014 to July2016were randomly divided into observation group（38cases）,control group（38cases）.After surgery,the control group was treated with routine treatment to prevent incidence of cerebral vasospasm and the observation group was treated with Buflomedil based on routine treatment to prevent cerebral vasospasm.Then compare the incidence of cerebral vasospasm,rate of adverse reactions compared and yhr indicators of serum S-100 B,EPO,MMP-9.Results：（1）The incidence of cerebral vasospasm was 5.26%in the observation group and 18.42%in the control group,and the difference was significant（P〈0.05）;（2）The improvement of serum EPO,MMP-9and S-100 Bin the observation group was better than that in the control group（P〈0.05）;（3）Adverse reaction rate：2.63%in the observation group and 5.26%in the control group,the difference was not statistically significant（P〈0.05）.Conclusion：The use of buflomedil in the prevention of cerebral vasospasm in patients with subarachnoid hemorrhage is conducive to achieving good prevention and reducing the incidence of cerebral vasospasm,which is worthy of clinical promotion.
出处
《数理医药学杂志》
2017年第9期1343-1345,共3页
Journal of Mathematical Medicine
